Company Overview and News
Larger and more financially healthy E&P companies are grouped together for analysis purposes in this "Tier One Producer" or "TOP Club"
CRC GDPMQ CHKVP PSX CRK QEP CHKVZ CRZO GDAOQ EGC EXXIQ SNZYP GDRRQ AMPY TALO SRCI EEXXQ BCEI RRS JONE WPX ESTE EXXI GDP CHK SGY TTEN MPOYQ SDRXP LINE SDRXQ APA HES DVN PVA EPE PIONF CHKDH CHKDG MCF CHKDJ ROSEU VNR CHKDP REI RSPP JNEEP AMR AMGP JAG ROSE LINEQ CKRGZ EVEP EOG RGRYY UPLMQ VNRCP PIO LNGG AR SWTF AM EXIXQ CHAP VNRBP SN XOG NBL WLL PDCE SM CTLR HKRCP SD RGRLF RRC DNR MPO VNRAP CLR GDPAN GDPAQ ECR CHPE UPL WPXP SDRPQ REN PE CXO RRL SCAZP AXAS COP AREX ECA SFY EVEPQ CDEV BRMR GDPM PVAYQ VNRR ECA SBOW CHKWZ GDUEQ SDOCQ GDANQ CHK.WI PVAC LPI WES HK HPR BRY
Healthier oil and natural gas prices have made the Energy sector an attractive investment opportunity. Our latest Earnings Trends shows that Energy will lead all Zacks Sectors to witness the strongest earnings growth in Q3.
CBSH CBSHP WLL HES RRL RRS CBCB RGRLF COP RRC RGRYY OXY
Chicago, IL –October 12, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Hess Corp. (HES - Free Report) , Northern Oil & Gas, Inc. (NOG - Free Report) , California Resources Corp. (CRC - Free Report) and Whiting Petroleum Corp.
CRC STLD WLL HES LB OUT
2018-10-11 zacks - 1
West Texas Intermediate (or WTI) — a benchmark for oil prices in the United States — recently hit four year high. The commodity popped above $76 a barrel, meaning that WTI oil surged almost 200% from the dark days of February 2016, when it fell to a 13-year low of around $26 per barrel.
CRC WLL HES
Kosmos Energy Ltd (KOS - Free Report) plans to abandon the well — the Pontoenoe-1 — in Block 42 offshore Suriname, after it failed to discover oil. This turned out to be the second dry well in the region in recent months. High-quality reservoir was discovered offshore Suriname but the main exploration goal proved to be water bearing. Also, the company did not encounter commercial hydrocarbons. Kosmos Energy, the exploration operator of Block 42, holds 33.
HES CVX KOS
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
The parent organization of CNOOC Limited (CEO - Free Report) , China National Offshore Oil Corporation, recently signed a production sharing contract (PSC) for Block 29/11 with Empyrean Energy PLC. The block is part of the prolific extensional sedimentary Pearl River Mouth basin, located in South China Sea. The PSC will start from Dec 13, 2018.
RDS.B RDS.A XOM HES RYDBF RDSB EME RDSA RYDAF CEO
2018-10-01 accesswire - 1
HOUSTON, TX / ACCESSWIRE / October 1, 2018 / PEDEVCO Corp. d/b/a Pacific Energy Development (NYSE American: PED) (the "Company") today announced that, effective September 27, 2018, the Company appointed H. Douglas Evans to the Company's Board of Directors and existing Board member John J. Scelfo to serve as its Chairman. In addition, the Company announced that all of the members of the Board have agreed to accept no cash compensation for their service on the Board, with Messrs.
Irina is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing on the oil and gas industry.
BEIJING (Reuters) - China’s CNOOC Ltd (0883.HK) is considering selling parts of its U.S. oil assets in the Gulf of Mexico, a company spokeswoman said on Thursday, but added that it does not intend to fully exit the U.S. market.
RDS.B RDS.A HES XOM RYDBF RDSB RDSA RYDAF CEO
BEIJING (Reuters) - China’s CNOOC Ltd (0883.HK) is considering selling parts of the stakes in oil assets in the Gulf of Mexico it has no plan to invest in exploration, a company spokeswoman said on Thursday.
RDS.B RDS.A HES RYDBF RDSB RDSA RYDAF CEO
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to HES / Hess Corp. on message board site Silicon Investor.
as of ET